🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud of Yohan Kim, PhD demonstrating the power of targeted EV isolation for detection of cancer-specific markers and enhance non-invasive prostate cancer diagnosis #ISEV2025 Mayo Clinic Urology

Packed room listening to Bernd Giebel and the use of MSC-derived EVs as therapeutic tools for human diseases. More work to do but first clinical evidence of efficacy. #ISEV2025

Cool! Red blood cell-derived EVs as tumor-targeting RNAi delivery systems. Great talk from Tram Nguyen (NUS, Singapore) #ISEV2025

🤩 This is going to be good! A discussion on key questions in the field with EV-superstar line-up: Eva-Maria Krämer-Albers, Clotilde Théry, Esther Nolte-'t Hoen, Ken Witwer, Hang Hubert Yin and Randy Carney #ISEV2025 Esther Nolte-'t Hoen Kenneth W Witwer (he/him) Eva-Maria Albers Hubert Yin

Happy for Chisom Uzendu, PhD candidate in my lab, co-chairing the Cancer & Metastasis session with David Lyden #ISEV2025

Mayo Clinic well represented at #ISEV2025 - 3 podium talks 7 posters on liquid biomarkers and functional roles of tumor-derived EVs Mayo Clinic Urology

Monique Bagwell from Mayo Clinic receiving an ISEV2025 Scholarship. Congratulations! #ISEV2025

#ISEV2025 scholarship winners! 👏

So proud of Chisom Uzendu, PhD candidate, for winning a Poster Award. Very well deserved. Mayo Clinic Urology

EVs flip-flops and sunglasses. #ISEV2026

“According to the White House document, the proposal would cut all non-defence spending by 23% but targets the US National Science Foundation for a 56% funding reduction, and would slash the budget of the US National Institutes of Health by roughly 40%.” nature.com/articles/d4158…

EV enthusiasts, we have a call for submission to the journal Clinical Proteomics. Method optimization, standardization and biomarker research on extracellular vesicles biomedcentral.com/collections/EV…

At Mayo, we have long recognized AI as a tool to enhance human expertise. @NYTimes takes a closer look at how our different view has allowed our radiologists to improve accuracy, accelerate diagnosis, and advance cures: nyti.ms/4knWFYj

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats Declan Murphy marlon perera + team European Association of Urology (EAU)! ➡️link shorturl.at/unfn5

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

Congrats to Mayo Clinic Urology researchers on their ⭐first-ever exploration of a new frontier in advanced urothelial carcinoma! Historically consolidative surgery was rare in metastatic UC but with unprecedented responses to EV/Pembro the paradigm is shifting. vist.ly/3n5mvyg

Thanks UroToday.com for highlighting our recent work on tumor-derived EVs for risk stratification and prediction of response to SBRT in omCSPC Mayo Clinic Urology Mayo Clinic Radiation Oncology

2️⃣ Metastasis Directed Therapy in Oligometastatic Prostate Cancer 👥 With Maneesh Singh & Piet Ost 🧠 A deep dive into MDT’s role: trial data, timing, integration with systemic Rx. 🚀 Covering both HSPC and CRPC. Read 📖 doi.org/10.1016/j.semr… With an image for the ages!

Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. Chad Tang, MD MD Anderson Cancer Center sits down with Leslie Ballas Cedars-Sinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic